FIAGX
Price
$19.39
Change
+$0.18 (+0.94%)
Updated
Apr 22, 6:59 PM EST
RERFX
Price
$56.47
Change
+$0.44 (+0.79%)
Updated
Apr 22, 6:59 PM EST
Ad is loading...

Analysis and predictions FIAGX vs RERFX

Header iconFIAGX vs RERFX Comparison
Open Charts FIAGX vs RERFXBanner chart's image
Fidelity Advisor International Growth A
Price$19.39
Change+$0.18 (+0.94%)
VolumeN/A
CapitalizationN/A
American Funds Europacific Growth R5
Price$56.47
Change+$0.44 (+0.79%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FIAGX vs RERFX Comparison Chart

Loading...

VS
FIAGX vs. RERFX commentary
Apr 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FIAGX is a Sell and RERFX is a Hold.

FUNDAMENTALS
Fundamentals
RERFX has more cash in the bank: 134B vs. FIAGX (5.49B). RERFX pays higher dividends than FIAGX: RERFX (1.79) vs FIAGX (0.18). FIAGX was incepted earlier than RERFX: FIAGX (16 years) vs RERFX (22 years). RERFX is a more actively managed with annual turnover of: 34.00 vs. FIAGX (22.00). FIAGX annual gain was more profitable for investors over the last year : 9.64 vs. RERFX (5.65). FIAGX return over 5 years is better than : 39.01 vs. RERFX (13.94).
FIAGXRERFXFIAGX / RERFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years22 years-
Gain YTD2.2143.36866%
Front LoadN/AN/A-
Min. Initial InvestmentN/A250-
Min. Initial Investment IRAN/AN/A-
Net Assets5.49B134B4%
Annual Yield % from dividends0.181.7910%
Returns for 1 year9.645.65171%
Returns for 3 years-1.26-17.427%
Returns for 5 years39.0113.94280%
Returns for 10 years77.4024.42317%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NXDT6.510.10
+1.56%
NexPoint Diversified Real Estate Trust
XYL128.981.14
+0.89%
Xylem
PEBO28.560.07
+0.25%
Peoples Bancorp
RELY18.40-0.11
-0.59%
Remitly Global
FBRX0.72-0.01
-1.91%
Forte Biosciences